Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation

Transplant International

Volumn 18, Issue 1, 2005, Pages 22-28

  Oberbauer, Rainer ^a   Segoloni, Giuseppe ^b   Campistol, Josep M ^c   Kreis, Henri ^d   Mota, Alfredo ^e   Lawen, Joseph ^f   Russ, Graeme ^g   Grinyó, Josep M ^h   Stallone, Giovanni ⁱ   Hartmann, Anders ^j   Pinto, Jose R ^k   Chapman, Jeremy ^l   Burke, James T ^m   Brault, Yves ^m   Neylan, John F ⁿ  

^a UNIVERSITY OF VIENNA   (Austria)

^b MOLINETTE HOSPITAL   (Italy)

^c HOSPITAL CLÍNIC   (Spain)

^d HÔPITAL NECKER ENFANTS MALADES   (France)

^e CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

^f QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^g QUEEN ELIZABETH HOSPITAL   (Australia)

^h HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

ⁱ UNIVERSITY OF BARI   (Italy)

^j OSLO UNIVERSITY HOSPITAL   (Norway)

^k HOSPITAL CURRY CABRAL   (Portugal)

^l WESTMEAD HOSPITAL   (Australia)

^m Clinical Research and Development   (France)

ⁿ PFIZER INC   (United States)

more..

Author keywords

Blood pressure; Cyclosporine withdrawal; Graft survival; Renal function; Sirolimus

Indexed keywords

CYCLOSPORIN A; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RAPAMYCIN; STEROID; CORTICOSTEROID; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT;

ABNORMAL SUBSTRATE CONCENTRATION IN BLOOD; ACNE; ACUTE GRAFT REJECTION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTHRALGIA; ARTHROPATHY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG WITHDRAWAL; EDEMA; GINGIVA HYPERPLASIA; GLOMERULUS FILTRATION RATE; GRAFT SURVIVAL; HERPES ZOSTER; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPERURICEMIA; HYPOKALEMIA; ILEUS; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT; KIDNEY BIOPSY; KIDNEY DISEASE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MEAN ARTERIAL PRESSURE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN TUMOR; STOMATITIS; THROMBOCYTOPENIA; CHEMICALLY INDUCED DISORDER; DRUG COMBINATION; DRUG EFFECT; FOLLOW UP; IMMUNOLOGY; KIDNEY TRANSPLANTATION; MORTALITY; PATIENT COMPLIANCE; PHYSIOLOGY; SURVIVAL; TIME;

ADRENAL CORTEX HORMONES; CYCLOSPORINE; DRUG THERAPY, COMBINATION; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; PATIENT COMPLIANCE; SIROLIMUS; STOMATITIS; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 21644457432     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2004.00052.x     Document Type: Article

References (18)

1. Meier-Kriesche HU, Schold JD, Kaplan B. Long-term renal allograft survival: have we made significant progress or is it time to rethink our analytic and therapeutic strategies? Am J Transplant 2004; 4: 1289.
2. Morales JM, Wramner L, Kreis H, et al. Sirolimus does not exhibit nephrotoxicity compared to cyclosporine in renal transplant recipients. Am J Transplant 2002; 2: 436.
3. Kahan BD, for The Rapamune US Study Group. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. Lancet 2000; 356: 194.
4. MacDonald AS, for The Rapamune Global Study Group. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/ cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation 2001; 71: 271.
5. Johnson RWG, Kreis H, Oberbauer R, Brattstrom C, Claesson K, Eris J. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation 2001; 72: 777.
6. Oberbauer R, Kreis H, Johnson RWG, et al. Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune Maintenance Regimen study. Transplantation 2003; 76: 364.
7. Kreis H, Oberbauer R, Campistol JM, et al. Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal. J Am Soc Nephrol 2004; 15: 809.
8. Mota A, Arias M, Taskinen EI, et al. Sirolimus-based therapy following early cyclosporine withdrawal provides significantly improved renal histology and function at 3 years. Am J Transplant 2004; 4: 953.
9. Hariharan S, McBride MA, Cherikh WS, Tolleris CB, Bresnahan BA, Johnson CP. Post-transplant renal function in the first year predicts long-term kidney transplant survival. Kidney Int 2002; 62: 311.
10. Kaplan B, Schold J, Meier-Kriesche HU. Poor predictive value of serum creatinine for renal graft loss. Am J Transplant 2003; 3: 1560.
11. Kasiske BL, Chakkera HA, Louis TA, Ma JZ. A meta-analysis of immunosuppression withdrawal trials in renal transplantation. J Am Soc Nephrol 2000; 11: 1910.
12. Abramowicz D, Gafner N, Wijngaard P. Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen: results of a five-year, prospective, randomized study. Am J Transplant 2004; 4 (Suppl. 8): 577.
13. Eisen HJ, Tuzcu EM, Dorent R, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003; 349: 847.
14. Mathew TH. A blinded, long-term, randomized multicenter study of mycophenolate mofetil in cadaveric renal transplantation: results at three years. Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation 1998; 65: 1450.
15. Gonwa T, Johnson C, Ahsan N, et al. Randomized trial of tacrolimus + mycophenolate mofetil or azathioprine versus cyclosporine + mycophenolate mofetil after cadaveric kidney transplantation: results at three years. Transplantation 2003; 75: 2048.
16. Kreis H, Cisterne JM, Land W, et al. for the Sirolimus European Renal Transplant Study Group. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 2000; 69: 1252.
17. Flechner SM, Goldfarb D, Modlin C, et al. Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine. Transplantation 2002; 74: 1070.
18. Flechner SM, Solez K, Cook DJ, et al. Kidney transplantation with sirolimus and mycophenolate mofetil based immunosuppression preserves renal structure and function compared to calcineurin inhibitor (CNI) drugs. Am J Transplant 2004; 4 (Suppl. 8): 296.